Report cover image

Live Attenuated Measles Vaccine Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 139 Pages
SKU # APRC20351985

Description

Summary

According to APO Research, the global Live Attenuated Measles Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Measles Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Measles Vaccine.

The report will help the Live Attenuated Measles Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Live Attenuated Measles Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Live Attenuated Measles Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Live Attenuated Measles Vaccine Segment by Company

GSK
Bavarian Nordic
CSL Limited
Emergent Biosolutions
Medimmune
Sanofi-Pasteur
Serum Institute of India
Beijing Institute of Biological Products Co., Ltd
Pfizer
Lanzhou Institute of Biological Products Co., Ltd
Merck
Novartis
Johnson & Johnson
Shanghai Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Measles Vaccine Segment by Type

Liquid
Powder
Live Attenuated Measles Vaccine Segment by Application

Hospital
Clinic
Live Attenuated Measles Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Live Attenuated Measles Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Live Attenuated Measles Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

139 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Live Attenuated Measles Vaccine Market Size (2020-2031)
2.2.2 Global Live Attenuated Measles Vaccine Sales (2020-2031)
2.2.3 Global Live Attenuated Measles Vaccine Market Average Price (2020-2031)
2.3 Live Attenuated Measles Vaccine by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Liquid
2.3.3 Powder
2.4 Live Attenuated Measles Vaccine by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
3.1 Global Live Attenuated Measles Vaccine Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Live Attenuated Measles Vaccine Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Live Attenuated Measles Vaccine Revenue of Manufacturers (2020-2025)
3.4 Global Live Attenuated Measles Vaccine Average Price by Manufacturers (2020-2025)
3.5 Global Live Attenuated Measles Vaccine Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
3.8 Global Manufacturers of Live Attenuated Measles Vaccine, Established Date
3.9 Global Live Attenuated Measles Vaccine Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 GSK
4.1.1 GSK Company Information
4.1.2 GSK Business Overview
4.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
4.1.5 GSK Recent Developments
4.2 Bavarian Nordic
4.2.1 Bavarian Nordic Company Information
4.2.2 Bavarian Nordic Business Overview
4.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
4.2.5 Bavarian Nordic Recent Developments
4.3 CSL Limited
4.3.1 CSL Limited Company Information
4.3.2 CSL Limited Business Overview
4.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
4.3.5 CSL Limited Recent Developments
4.4 Emergent Biosolutions
4.4.1 Emergent Biosolutions Company Information
4.4.2 Emergent Biosolutions Business Overview
4.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
4.4.5 Emergent Biosolutions Recent Developments
4.5 Medimmune
4.5.1 Medimmune Company Information
4.5.2 Medimmune Business Overview
4.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
4.5.5 Medimmune Recent Developments
4.6 Sanofi-Pasteur
4.6.1 Sanofi-Pasteur Company Information
4.6.2 Sanofi-Pasteur Business Overview
4.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
4.6.5 Sanofi-Pasteur Recent Developments
4.7 Serum Institute of India
4.7.1 Serum Institute of India Company Information
4.7.2 Serum Institute of India Business Overview
4.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
4.7.5 Serum Institute of India Recent Developments
4.8 Beijing Institute of Biological Products Co., Ltd
4.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
4.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
4.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
4.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
4.9 Pfizer
4.9.1 Pfizer Company Information
4.9.2 Pfizer Business Overview
4.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
4.9.5 Pfizer Recent Developments
4.10 Lanzhou Institute of Biological Products Co., Ltd
4.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
4.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
4.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
4.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
4.11 Merck
4.11.1 Merck Company Information
4.11.2 Merck Business Overview
4.11.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
4.11.5 Merck Recent Developments
4.12 Novartis
4.12.1 Novartis Company Information
4.12.2 Novartis Business Overview
4.12.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
4.12.5 Novartis Recent Developments
4.13 Johnson & Johnson
4.13.1 Johnson & Johnson Company Information
4.13.2 Johnson & Johnson Business Overview
4.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
4.13.5 Johnson & Johnson Recent Developments
4.14 Shanghai Institute of Biological Products Co., Ltd
4.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
4.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
4.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
4.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
4.15 Wuhan Institute of Biological Products Co., Ltd
4.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
4.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
4.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
4.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
4.16 Changchun Qijian Biological Products Co., Ltd
4.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
4.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
4.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
4.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
5 Global Live Attenuated Measles Vaccine Market Scenario by Region
5.1 Global Live Attenuated Measles Vaccine Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Live Attenuated Measles Vaccine Sales by Region: 2020-2031
5.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2020-2025
5.2.2 Global Live Attenuated Measles Vaccine Sales by Region: 2026-2031
5.3 Global Live Attenuated Measles Vaccine Revenue by Region: 2020-2031
5.3.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2020-2025
5.3.2 Global Live Attenuated Measles Vaccine Revenue by Region: 2026-2031
5.4 North America Live Attenuated Measles Vaccine Market Facts & Figures by Country
5.4.1 North America Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Live Attenuated Measles Vaccine Sales by Country (2020-2031)
5.4.3 North America Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Live Attenuated Measles Vaccine Market Facts & Figures by Country
5.5.1 Europe Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Live Attenuated Measles Vaccine Sales by Country (2020-2031)
5.5.3 Europe Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Live Attenuated Measles Vaccine Market Facts & Figures by Country
5.6.1 Asia Pacific Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2020-2031)
5.6.3 Asia Pacific Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Live Attenuated Measles Vaccine Market Facts & Figures by Country
5.7.1 South America Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Live Attenuated Measles Vaccine Sales by Country (2020-2031)
5.7.3 South America Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Live Attenuated Measles Vaccine Market Facts & Figures by Country
5.8.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2020-2031)
5.8.3 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Live Attenuated Measles Vaccine Sales by Type (2020-2031)
6.1.1 Global Live Attenuated Measles Vaccine Sales by Type (2020-2031) & (K Units)
6.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2020-2031)
6.2 Global Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
6.2.1 Global Live Attenuated Measles Vaccine Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2020-2031)
6.3 Global Live Attenuated Measles Vaccine Price by Type (2020-2031)
7 Segment by Application
7.1 Global Live Attenuated Measles Vaccine Sales by Application (2020-2031)
7.1.1 Global Live Attenuated Measles Vaccine Sales by Application (2020-2031) & (K Units)
7.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2020-2031)
7.2 Global Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
7.2.1 Global Live Attenuated Measles Vaccine Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2020-2031)
7.3 Global Live Attenuated Measles Vaccine Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Live Attenuated Measles Vaccine Value Chain Analysis
8.1.1 Live Attenuated Measles Vaccine Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Live Attenuated Measles Vaccine Production Mode & Process
8.2 Live Attenuated Measles Vaccine Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Live Attenuated Measles Vaccine Distributors
8.2.3 Live Attenuated Measles Vaccine Customers
9 Global Live Attenuated Measles Vaccine Analyzing Market Dynamics
9.1 Live Attenuated Measles Vaccine Industry Trends
9.2 Live Attenuated Measles Vaccine Industry Drivers
9.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
9.4 Live Attenuated Measles Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.